Oslo, Norway, October 2, 2024 - EXACT Therapeutics AS (Euronext Growth: EXTX), a
clinical stage precision medicine company utilizing the power of ultrasound to
enable targeted drug delivery in oncology, today announced that it will be
giving a presentation at the upcoming bi-annual Contrast Media Research (CMR)
Symposium 2024, taking place October 6-9, 2024, in Oslo, Norway. Chief Executive
Officer Per Walday will be giving a presentation on the promising ACTIVATE Phase
1 trial in patients with liver metastases of colorectal origin.
Details of the presentation are as follows:
Presentation title: First-in-Human Study of Acoustic Cluster Therapy with
Chemotherapy and in Patients with Liver Metastases of Colorectal Cancer Origin
Place: Ultrasound Imaging 2 sessions on Tuesday, October 8th at 9:45 a.m. (local
time)
The company presentation will be made available at the Investors section the
Company's website: https://exact-tx.com/finreports
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com
About EXACT Therapeutics
EXACT is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to enable or significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy) and brain
diseases. www.exact-tx.com
About ACT®
o ACT is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
o ACT is being tested in the clinic and has released positive interim data. It
is supported by a strong and broad preclinical package demonstrating therapeutic
enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as
well as blood-brain barrier penetration.
o Initial focus of the company is oncology. The ACT platform has potential
across many therapeutic areas (including CNS, immunotherapy) and product
classes.
Forward looking statements:
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.